Bipolar Disorder
Conditions
Interventions
1:Bright Light Therapy Combined With Mood Stabilizers
2:dim Red Light Therapy Combined With Mood Stabilizers
Sponsors
Peking University Sixth Hospital (Peking University Institute of Mental Health)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. aged 18 to 65 years; 2. Meet with the DSM-IV diagnosis of Bipolar I or II Disorder and a current depressive episode; 3. The duration time less than one year,untreated by systematic antidepressant and HAMD score =17 points at baseline; 4. Based on patients'symptoms, treating Bipolar disorder with quetiapine monotherapy, or quetiapine combined with valproate, or quetiapine combined with lithium, in which the daily dose of quetiapine ranging from 100mg to 400mg and the dose of valproate and lithium being fixed for at least 2 weeks.;Inclusion criteria: 1. aged 18 to 65 years; 2. Meet with the DSM-IV diagnosis of Bipolar I or II Disorder and a current depressive episode; 3. The duration time less than one year,untreated by systematic antidepressant and HAMD score =17 points at baseline; 4. Based on patients'symptoms, treating Bipolar disorder with quetiapine monotherapy, or quetiapine combined with valproate, or quetiapine combined with lithium, in which the daily dose of quetiapine ranging from 100mg to 400mg and the dose of valproate and lithium being fixed for at least 2 weeks.;Inclusion criteria: 1. aged 18 to 65 years; 2. Meet with the DSM-IV diagnosis of Bipolar I or II Disorder and a current depressive episode; 3. The duration time less than one year,untreated by systematic antidepressant and HAMD score =17 points at baseline; 4. Based on patients'symptoms, treating Bipolar disorder with quetiapine monotherapy, or quetiapine combined with valproate, or quetiapine combined with lithium, in which the daily dose of quetiapine ranging from 100mg to 400mg and the dose of valproate and lithium being fixed for at least 2 weeks.;Inclusion criteria: 1. aged 18 to 65 years; 2. Meet with the DSM-IV diagnosis of Bipolar I or II Disorder and a current depressive episode; 3. The duration time less than one year,untreated by systematic antidepressant and HAMD score =17 points at baseline; 4. Based on patients'symptoms, treating Bipolar disorder with quetiapine monotherapy, or quetiapine combined with valproate, or quetiapine combined with lithium, in which the daily dose of quetiapine ranging from 100mg to 400mg and the dose of valproate and lithium being fixed for at least 2 weeks.;Inclusion criteria: 1. aged 18 to 65 years; 2. Meet with the DSM-IV diagnosis of Bipolar I or II Disorder and a current depressive episode; 3. The duration time less than one year,untreated by systematic antidepressant and HAMD score =17 points at baseline; 4. Based on patients'symptoms, treating Bipolar disorder with quetiapine monotherapy, or quetiapine combined with valproate, or quetiapine combined with lithium, in which the daily dose of quetiapine ranging from 100mg to 400mg and the dose of valproate and lithium being fixed for at least 2 weeks.
Exclusion criteria
Exclusion criteria: 1. YMRS score=12 points at baseline; 2. high suicide risk; 3. previous ineffective for quetiapine or not tolerate to quetiapine; 4. received magnified electroconvulsive therapy orRepetitive Transcranial Magnetic Stimulation in the past 3 months; 5. significant medical illness such as diabetes mellitus,heart failure, renal failure, severe liver function abnormalities,hyperthyroidism or hypothyroidism; 6. pregnant or breast-feeding 7. with eye contact disease (cataract, glaucoma, high myopia, retinal detachment, optic atrophy, macular degeneration, etc.); 8. others, sucn as apastia, negativism or stupor.;Exclusion criteria: 1. YMRS score=12 points at baseline; 2. high suicide risk; 3. previous ineffective for quetiapine or not tolerate to quetiapine; 4. received magnified electroconvulsive therapy orRepetitive Transcranial Magnetic Stimulation in the past 3 months; 5. significant medical illness such as diabetes mellitus,heart failure, renal failure, severe liver function abnormalities,hyperthyroidism or hypothyroidism; 6. pregnant or breast-feeding 7. with eye contact disease (cataract, glaucoma, high myopia, retinal detachment, optic atrophy, macular degeneration, etc.); 8. others, sucn as apastia, negativism or stupor.;Exclusion criteria: 1. YMRS score=12 points at baseline; 2. high suicide risk; 3. previous ineffective for quetiapine or not tolerate to quetiapine; 4. received magnified electroconvulsive therapy orRepetitive Transcranial Magnetic Stimulation in the past 3 months; 5. significant medical illness such as diabetes mellitus,heart failure, renal failure, severe liver function abnormalities,hyperthyroidism or hypothyroidism; 6. pregnant or breast-feeding 7. with eye contact disease (cataract, glaucoma, high myopia, retinal detachment, optic atrophy, macular degeneration, etc.); 8. others, sucn as apastia, negativism or stupor.;Exclusion criteria: 1. YMRS score=12 points at baseline; 2. high suicide risk; 3. previous ineffective for quetiapine or not tolerate to quetiapine; 4. received magnified electroconvulsive therapy orRepetitive Transcranial Magnetic Stimulation in the past 3 months; 5. significant medical illness such as diabetes mellitus,heart failure, renal failure, severe liver function abnormalities,hyperthyroidism or hypothyroidism; 6. pregnant or breast-feeding 7. with eye contact disease (cataract, glaucoma, high myopia, retinal detachment, optic atrophy, macular degeneration, etc.); 8. others, sucn as apastia, negativism or stupor.;Exclusion criteria: 1. YMRS score=12 points at baseline; 2. high suicide risk; 3. previous ineffective for quetiapine or not tolerate to quetiapine; 4. received magnified electroconvulsive therapy orRepetitive Transcranial Magnetic Stimulation in the past 3 months; 5. significant medical illness such as diabetes mellitus,heart failure, renal failure, severe liver function abnormalities,hyperthyroidism or hypothyroidism; 6. pregnant or breast-feeding 7. with eye contact disease (cataract, glaucoma, high myopia, retinal detachment, optic atrophy, macular degeneration, etc.); 8. others, sucn as apastia, negativism or stupor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale;Young Mania Rating Scale;16-item Quick Inventory of Depressive Symptomatology, Self-report (QIDS-SR16);Clinical Global Impression;Hypomania Symptom Checklist-32; | — |
Secondary
| Measure | Time frame |
|---|---|
| Social Disability Screening Schedule;assessment of the neurocognition; | — |
Countries
China
Contacts
Public ContactYantao Ma;Yantao Ma;Yantao Ma;Yantao Ma;Yantao Ma ;;;;
Peking University Sixth Hospital (Peking University Institute of Mental Health);Peking University Sixth Hospital (Peking University Institute of Mental Health);Peking University Sixth Hospital (Peking University Institute of Mental Health);Peking University Sixth Hospital (Peking University Institute of Mental Health);Peking University Sixth Hospital (Peking University Institute of Mental Health)
Outcome results
None listed